On February 11, 2021 Australian clinical-stage drug development company, Noxopharm, reported the publication of the latest survival data from the LuPIN study ahead of their formal presentation to the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (February 11-13, 2021), the preeminent medical conference dedicated to sharing the most recent innovations in the treatment of genitourinary cancers (Press release, Noxopharm, FEB 11, 2021, View Source [SID1234574952]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The results showed a median overall survival (mOS) of 19.7 months, exceeding all other mOS results for existing prostate cancer treatments in their own registration studies. This supports evidence that a combination of Veyonda (NOX66) and the experimental radiopharmaceutical, 177lutetium-PSMA-617, is a long-awaited leap forward in the treatment of metastatic castrate-resistant prostate cancer (mCRPC). This offers a patient with mCRPC a high chance of the cancer responding to treatment to the extent of obtaining a meaningful survival outcome.
"This clinical data continues to cement the view that Veyonda is on track to become a major new immunotherapy oncology drug of medical and commercial significance," said Noxopharm CEO Dr. Graham Kelly. "The investigators chose to test the LuPIN combination in men with end-stage disease as being the most stringent test possible. Providing men at this stage with an opportunity to achieve about an average of 20 months of life, with obviously more in some men, is an extraordinary outcome. This could potentially revolutionize the treatment of end-stage prostate cancer."
The study enrolled a total of 56 patients whose cancers had progressed to an advanced stage despite standard therapy. The goal of the combined treatment was to slow or block tumor progression to deliver better quality of life and extended survival for these men, and to do so in a well-tolerated way.
Noxopharm sees the next step as taking the combination further upstream in the treatment process with a view to it becoming an early standard-of-care treatment.